This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Gastrointestinal disease				
Pancreatitis	CD38	<p>Cell culture and mouse studies suggest antagonizing CD38 could be useful for treating pancreatitis. In cultured mouse pancreatic acinar cells, <i>Cd38</i> deletion decreased calcium release and cell injury in response to excessive stimulation compared with wild-type <i>Cd38</i> expression. In a mouse model of bile acid-induced pancreatitis, <i>Cd38</i> knockout mice had less damage than wild-type mice. Next steps include testing CD38 mAbs in cellular and mouse models of pancreatitis.</p> <p>Anti-CD38 mAbs in Phase I/II testing for multiple myeloma (MM) include MOR202 from Celgene Corp. and MorphoSys AG, daratumumab from Genmab A/S and Johnson & Johnson and SAR650984 from Sanofi.</p> <p>SciBX 6(38); doi:10.1038/scibx.2013.1064 Published online Oct. 3, 2013</p>	Patent and licensing status undisclosed	<p>Orabi, A.I. <i>et al. J. Biol. Chem.</i>; published online Aug. 12, 2013; doi:10.1074/jbc.M113.494534</p> <p>Contact: Sohail Z. Husain, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pa. e-mail: sohail.husain@chp.edu</p>